Meeting Archives
Chemotherapy Foundation Symposium XXIV
November 10-13, 2004
Marriott Marquis Hotel , New York , NY
Highlights
| NEUTROPENIA IN 1ST CYCLE OF CHEMOTHERAPY: IMPACT OF PEG-FILGRASTIM Janice L. Gabrilove, M.D. |
View Presentation |
| FEBRILE NEUTROPENIA IN DOCETAXEL-TREATED BREAST CANCER: EVALUATING
PEGFILGRASTIM Charles Vogel, M.D. |
View Presentation |
| CANCER TREATMENT-INDUCED BONE LOSS: EMERGING PROBLEM IN BREAST
AND PROSTATE CANCER Allan Lipton, M.D. |
View Presentation |
| PANITUMUMAB: A HUMAN ANTI-EGFR ANTIBODY IN COLORECTAL CANCER J. Randolph Hecht, M.D. |
View Presentation |
Supported by an Educational Grant
from Amgen |
|
| ZEVALIN IN DIFFUSE LARGE B-CELL LYMPHOMA Robin M. Joyce, M.D. |
View Presentation |
| R-CHOP FOLLOWED BY ZEVALIN IN FOLLICULAR NHL John D. Hainsworth, M.D. |
View Presentation |
| UTILIZING RADIOIMMUNOTHERAPY: CONSIDERATIONS FOR THE ONCOLOGY
TEAM Jennifer Fiore, R.N., M.A., A.N.P-C, O.C.N. |
View Presentation |
Supported by an Educational Grant
from Biogen Idec |
|
| ANGIOGENESIS IN COLORECTAL CANCER Heinz-Josef Lenz, M.D. |
View Presentation |
| GEMCITABINE AND CARBOPLATIN IN SECOND LINE OVARIAN CANCER Robert F. Ozols, M.D., Ph.D. |
View Presentation |
| EGFR TESTING AND INTERPRETATION Meera Hameed, M.D. |
View Presentation |
| EGFR EXPRESSION RASH: ASSESSMENT, GRADING, TREATMENT Madeleine Duvic, M.D. |
View Presentation |
| UPDATE ON EGFR INHIBITORS IN NSCLC Roy Herbst, M.D., Ph.D. |
View Presentation |
| CETUXIMAB IN CHEMORADIATION IN LOCALLY ADVANCED NSCLC Corey Langer, M.D. |
View Presentation |
| NOVEL APPROACHES TO ESOPHAGOGASTRIC CANCER Peter C. Enzinger, M.D. |
View Presentation |
Supported by an Educational Grant
from Bristol-Myers Squibb Oncology |
|
| LENALIDOMIDE (REVLIMID) FOR ANEMIA IN MYELODYSPLASTIC SYNDROMES Alan List, M.D. |
View Presentation |
| REVLIMID (LENALIDOMIDE) IN RENAL CELL CANCER Robert J. Amato, M.D. |
View Presentation |
| THALIDOMIDE AND GEMCITABINE IN FIRST LINE PANCREATIC CANCER William Maples, M.D. |
View Presentation |
Supported by an Educational Grant
from Celgene |
|
| AVASTIN AND TARCEVA IN NSCLC Roy Herbst, M.D., Ph.D. |
View Presentation |
| ANGIOGENESIS IN COLORECTAL CANCER Heinz-Josef Lenz, M.D. |
View Presentation |
| BEVACIZUMAB PLUS GEMCITABINE FOR ADVANCED PANCREATIC CANCER Hedy Kindler, M.D. |
View Presentation |
| OXALIPLATIN/FLUOROPYRIMIDE/AVASTIN IN METASTATIC COLORECTAL
CANCER Howard S. Hochster, M.D. |
View Presentation |
Supported by an Educational Grant
from Genentech BioOncology |
|
| WEEKLY SCHEDULES IN OVARIAN CANCER Deborah Armstrong, M.D. |
View Presentation |
| UPDATE ON CERVICAL CANCER THERAPY Harry J. Long, M.D. |
View Presentation |
| INHIBITION OF erbB PATHWAYS IN LUNG CANCER Afshin Dowlati, M.D. |
View Presentation |
Supported by an Educational Grant
from GlaxoSmithKline |
|
| DENILEUKIN DIFTITOX AS NOVEL THERAPY FOR HEMATOLOGIC MALIGNANCIES Nam Dang, M.D., Ph.D. |
View Presentation |
| PAIN MANAGEMENT: STILL AN ISSUE? Larry Driver, M.D. |
View Presentation |
Supported by an Educational Grant
from Ligand Pharmacxeuticals |
|
| GEMCITABINE PLUS PACLITAXEL IN BREAST CANCER Denise Yardley, M.D. |
View Presentation |
| PEMETREXED PLUS CARBOPLATIN OR OXALIPLATIN IN NSCLC Gorgio Scagliotti, M.D. |
View Presentation |
| CYTOTOXIC THERAPY IN PS 2 ADVANCED NSCLC Cory Langer, M.D. |
View Presentation |
| CHEMOTHERAPEUTIC DOUBLETS IN PANCREATIC CANCER Donald Richards, M.D. |
View Presentation |
Supported by an Educational Grant from Lilly Oncology |
|
| ROLE OF LETROZOLE IN ADJUVANT THERAPY William J. Gradishar, M.D. |
View Presentation |
| EPOTHILONES: CLINICAL DEVELOPMENTS Edward S. Kim, M.D. |
View Presentation |
| ANTIANGIOGENIC THERAPY WITH VEGF OR VEGF RECEPTOR TARGETING AGENTS Robert S. Kerbel, Ph.D. |
View Presentation |
| CLINICAL UPDATE ON THE NOVEL mTOR-INHIBITOR RAD001 Howard A. Burris, III, M.D. |
View Presentation |
| RATIONAL TREATMENT OPTIONS FOR GIST: GLEEVEC, SU11248, RAD001,
AND BEYOND George D. Demetri, M.D. |
View Presentation |
Supported by an Educational Grant from Novartis Oncology |
|
| CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER Daniel F. Hayes, M.D. |
View Presentation |
| LONG TERM SURVIVAL ADVANTAGE: LIPOSOMAL DOXORUBICIN PHASE II STUDY
IN OVARIAN CANCER Alan N. Gordon, M.D. |
View Presentation |
| DOXIL: MAKING DOXORUBICIN WORK IN OVARIAN AND ENDOMETRIAL CANCERS Franco M. Muggia, M.D. |
View Presentation |
| EVALUATING OPTIONS IN CHEMOTHERAPY-INDUCED ANEMIA Roger Waltzman, M.D. |
View Presentation |
| YONDELIS – A NEW AGENT FOR THE TREATMENT OF SARCOMA Brian L. Samuels, M.D. |
View Presentation |
| IMPLEMENTING BEST PRACTICES AND APPROPRIATE USE GUIDELINES Dwight Kloth, Pharm.D., F.C.C.P., B.C.O.P |
View Presentation |
Supported by an Educational Grant from Ortho Biotech Oncology, Tibotec Therapeutics |
|
| TEMOZOLOMIDE AND IRINOTECAN IN RECURRENT MALIGNANT ASTROCYTOMA Michael Gruber, M.D. |
View Presentation |
| IRINOTECAN/CISPLATINUM VS. ETOPOSIDE/CISPLATINUM IN SCLC Alan B. Sandler, M.D. |
View Presentation |
| SUGEN11248: A MULTITARGETED TYROSINE KINASE INHIBITOR IN METASTATIC
KIDNEY CANCER Robert J. Motzer, M.D. |
View Presentation |
| LOW MOLECULAR WEIGHT HEPARINS IN THE MANAGEMENT OF MALIGNANCY-ASSOCIATED
THROMBOSIS Jawed Fareed, Ph.D. |
View Presentation |
| TAMOXIFEN AND EXEMESTANE IN THE METASTATIC AND ADJUVANT SETTINGS:
TRIAL RESULTS Stephen E. Jones, M.D. |
View Presentation |
| NEW STRATEGIES FOR ANTHRACYCLINE USE IN EARLY BREAST CANCER Edith Perez, M.D. |
View Presentation |
| HORMONAL TREATMENT OF BREAST CANCER: PROGRESS AND DIRECTIONS Maura N. Dickler, M.D. |
View Presentation |
| REMISSION RATE ADVANTAGE WITH NEOADJUVANT TRASTUZUMAB, PACLITAXEL AND
EPIRUBICIN-CONTAINING CHEMOTHERAPY Aman U. Buzdar, M.D. |
View Presentation |
Supported by an Educational Grant from Pfizer Oncology |
|
| ORAL CHEMOTHERAPY FOR METASTATIC BREAST CANCER Julie R. Gralow, M.D. |
View Presentation |
| ORAL ADJUVANT CHEMOTHERAPY IN COLORECTAL CANCER Christopher Twelves, M.D. |
View Presentation |
| OPTIONS WITH ORAL CHEMOTHERAPY IN CRC Edward Chu, M.D |
View Presentation |
Supported by an Educational Grant from Roche Laboratories |
|
| THERAPEUTIC OPTIONS IN ADVANCED PROSTATE CANCER Daniel Petrylak, M.D. |
View Presentation |
| ADJUVANT THERAPY IN HORMONE REFRACTORY PROSTATE CANCER Mario Eisenberger, M.D. |
View Presentation |
| UPDATE ON DOCETAXEL IN HEAD AND NECK CANCER Marshall R. Posner, M.D. |
View Presentation |
| OVERVIEW OF NEOADJUVANT AND ADJUVANT THERAPY FOR NSCLC Chandra P. Belani, M.D. |
View Presentation |
| OXALIPLATIN AS ADJUVANT THERAPY OF COLON CANCER Daniel Haller, M.D. |
View Presentation |
| QOL AND PHARMACOECONOMICS: ENDPOINTS IN ADJUVANT THERAPY FOR COLON
CANCER John L. Marshall, M.D. |
View Presentation |
| OXALIPLATIN-BASED REGIMENS IN COMBINATION WITH BEVACIZUMAB IN COLORECTAL
CANCER Edward Chu, M.D |
View Presentation |
| OXALIPLATIN/FLUOROPYRIMIDE/AVASTIN IN METASTATIC COLORECTAL CANCER Howard S. Hochster, M.D. |
View Presentation |
Supported by an Educational Grant from Sanofi-Aventis |
|
| EXPERIENCE WITH DECITABINE IN CML AND MDS Hagop Kantarjian, M.D. |
View Presentation |
| TREATMENT OF MDS WITH HYPOMETHYLATING AGENTS Stephen D. Nimer, M.D. |
View Presentation |
| UPDATE ON RUBITECAN IN SOLID TUMORS Emiliano Calvo, M.D. |
View Presentation |
| PREVENTION TARGETS IN p16INK4a METHYLATED EPITHELIAL CELLS Mona Gauthier, M.D. |
View Presentation |
Supported by an Educational Grant from SuperGen |
|
